Epalrestat, an aldose reductase inhibitor, improves an impaired generation of oxygen-derived free radicals by neutrophils from poorly controlled NIDDM patients

Diabetes Care
N SatoM Mori

Abstract

To study the in vivo effect of epalrestat (Epa), an aldose reductase inhibitor, on the generation of oxygen-derived free radicals by neutrophils from poorly controlled NIDDM patients (HbA1c > 10%). A total of 31 diabetic patients were randomly divided into two groups: an Epa(+) group of 16 patients treated with 150 mg/day epalrestat and an Epa(-) group of 15 patients treated without epalrestat. A control group of 20 age- and sex-matched normal healthy subjects also participated. HbA1c, postprandial plasma glucose (PPG), and neutrophil bactericidal function were measured before and at the end of the drug treatment period (4 weeks). Neutrophil bactericidal function was measured as chemilu-minescence amplified by a Cypridina luciferin analog (CLA), which is dependent on O2- generation, and by luminol (L), which is highly dependent on OCl- generation, in response to formyl-methonyl-leucyl-phenylalanine (fMLP). At the start of the experiment, both CLA-dependent chemiluminescence (CLA-DCL) and L-dependent chemiluminescence (L-DCL) were clearly decreased in diabetic subjects (64 and 54%, respectively; P < 0.05) compared with control subjects (2,182 +/- 144 and 3,221 +/- 173 kc.min-1.10(-6) cells, respectively). At the end of the exper...Continue Reading

Citations

Nov 8, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G EngelichK L Hartshorn
Dec 30, 2010·Journal of Periodontology·Peter F KadorRichard A Reinhardt
May 3, 2007·AACN Advanced Critical Care·Julia Lindeman Read, Eugene Y Cheng
Sep 9, 2006·Diabetes/metabolism Research and Reviews·Anton Y PelegTimothy M E Davis
Jan 30, 2004·Diabetes Care·Stephen ClementUNKNOWN American Diabetes Association Diabetes in Hospitals Writing Committee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.